Testosterone Enanthate Pre-Surgery Hold Window: Clinical Guide

Why the Pre-Surgery Hold Exists

Testosterone enanthate raises hematocrit and activates platelet aggregation pathways, two changes that compound the already-elevated clotting risk of surgery. Stopping the drug 4 to 6 weeks before an elective procedure allows serum testosterone to return toward baseline and gives erythrocytosis time to partially resolve, reducing the thrombogenic burden during the perioperative window.

The Pharmacokinetic Basis for a 4-to-6-Week Hold

Testosterone enanthate has a mean elimination half-life of approximately 4.5 days after intramuscular injection [1]. Five half-lives project full pharmacokinetic washout at roughly 22 to 23 days. The 4-to-6-week hold extends beyond that timeline deliberately. Erythropoietic effects persist longer than circulating drug levels because mature red blood cells survive 90 to 120 days; a 4-to-6-week hold trims peak hematocrit by reducing new erythropoietic drive without waiting for full red-cell turnover.

A single 200 mg IM dose produces peak serum testosterone at 24 to 72 hours, followed by a gradual decline over 7 to 10 days [2]. Patients on every-two-week dosing who stop injections 4 weeks before surgery will therefore have negligible circulating ester by the day of their procedure, while hematocrit will have begun trending down from its peak.

Erythrocytosis and Surgical Clot Risk

Hematocrit above 54% is the threshold at which the Endocrine Society 2018 Clinical Practice Guideline recommends withholding testosterone entirely, regardless of the surgical calendar [3]. Surgery amplifies this risk through venous stasis (immobility, pneumoperitoneum), endothelial injury, and a systemic procoagulant shift. The combination of exogenous-testosterone-driven erythrocytosis plus surgical hemostasis activation creates conditions favorable for deep vein thrombosis and pulmonary embolism.

A 2019 pharmacoepidemiologic analysis published in BMJ Open found that men on exogenous testosterone carried approximately a 1.5-fold higher rate of venous thromboembolism compared to age-matched controls not receiving testosterone [4]. That baseline excess, layered onto surgical VTE rates of 0.5% to 3% for general procedures (rising to 40% to 60% without prophylaxis for major orthopedic surgery), provides the quantitative rationale for a planned hold [5].

Prothrombotic Mechanisms Beyond Red Cells

Erythrocytosis is the most-cited mechanism, but testosterone's effects on coagulation extend further. The drug modulates plasminogen activator inhibitor-1 (PAI-1), fibrinogen, and platelet thromboxane A2 receptor density, each of which can shift hemostasis toward thrombosis [6].

PAI-1 and Fibrinolysis Suppression

PAI-1 is the principal inhibitor of tissue plasminogen activator (tPA). Elevated PAI-1 slows clot breakdown. Several studies show that supraphysiologic testosterone raises PAI-1 activity, though findings at physiologic replacement doses are more mixed [6]. Surgical stress itself suppresses fibrinolysis transiently; adding a pharmacologic PAI-1 increment from testosterone narrows the therapeutic window for intraoperative thrombolytic balance.

Platelet Activation

Testosterone up-regulates thromboxane A2 receptor expression on platelets in vitro and in some clinical cohorts, increasing platelet aggregability [7]. This effect is partially independent of hematocrit. For a patient whose pre-op platelet function testing already shows hyperaggregability, the clinical team needs to know whether testosterone is a contributing variable, a detail that only a documented hold window makes interpretable.

Polycythemia Vera vs. Exogenous Erythrocytosis

Anesthesiologists sometimes encounter a patient with hematocrit of 58% and an ambiguous history. Distinguishing testosterone-driven secondary polycythemia from polycythemia vera changes the management plan entirely. A documented 6-week hold with repeat CBC before surgery provides a controlled experiment: if hematocrit normalizes after the hold, exogenous androgen was the driver. If it remains elevated, JAK2 V617F mutation testing and hematology consultation are warranted before proceeding.

What the T-Trials Tell Surgeons

The Testosterone Trials (T-Trials) were a coordinated set of seven double-blind, placebo-controlled trials enrolling 790 men aged 65 or older with unambiguously low testosterone (<275 ng/dL) [8]. Published in the New England Journal of Medicine in 2016, the primary sexual-function, physical-function, and vitality trials showed that testosterone gel (not enanthate specifically, but the same androgen) improved sexual activity scores, walking distance over 6 minutes, and self-reported vitality relative to placebo [8].

The T-Trials also provided some of the most rigorous safety data available. Hematocrit rose to above 54% in 5.9% of testosterone-treated men versus 0.8% in the placebo group (P<0.001) [8]. Cardiovascular events were numerically higher in the testosterone arm, though the trial was not powered to adjudicate that outcome statistically. The FDA subsequently required a class-wide label update in 2015 warning of possible increased cardiovascular risk with testosterone products [9].

For surgeons and anesthesiologists, the T-Trials hematocrit data are directly actionable: nearly 1 in 17 men on therapeutic testosterone will breach the 54% hematocrit threshold that already warrants hold and possible phlebotomy. Pre-operative screening CBC is therefore mandatory for any testosterone enanthate patient scheduled for elective surgery.

The HealthRX Perioperative Hold Protocol for Testosterone Enanthate

The following decision framework consolidates Endocrine Society guideline thresholds [3], American Society of Hematology VTE guidance [5], and pharmacokinetic modeling [1,2] into a single clinical workflow.

Step 1: Confirm Last Injection Date and Dosing Interval

At the surgical consultation, record the exact date of the patient's most recent testosterone enanthate injection and the prescribed interval (typically every 7 or every 14 days). Calculate the number of days to the planned surgical date. If fewer than 28 days remain, flag the case for attending anesthesia review, the pharmacokinetic washout will be incomplete.

Step 2: Order Pre-Hold Labs

Draw a CBC with differential, comprehensive metabolic panel, and lipid panel before the patient stops testosterone. This establishes a baseline hematocrit and hemoglobin from which post-hold and post-surgical changes can be measured. If hematocrit is already above 54%, therapeutic phlebotomy (500 mL) may be indicated before the hold begins, per Endocrine Society criteria [3].

Step 3: Stop Testosterone Enanthate 4 to 6 Weeks Before Surgery

The patient skips scheduled injections during this window. No bridging agent is used. Symptomatic hypogonadal patients (severe fatigue, mood disturbance) may benefit from a brief discussion of expected withdrawal symptoms, which typically resolve within 10 to 14 days as the body's hypothalamic-pituitary-gonadal axis begins to recover modest endogenous output, though full HPG recovery takes considerably longer in long-term users.

Step 4: Repeat CBC 1 Week Before Surgery

A hematocrit above 52% at this check warrants same-day anesthesia consultation. A hematocrit above 54% should prompt surgical postponement until the value normalizes, unless the case is urgent or emergent.

Step 5: Restart Decision Post-Operatively

Restart testosterone enanthate no sooner than 2 weeks after surgery for low-risk ambulatory procedures, and no sooner than 4 weeks after major inpatient surgery (orthopedic, abdominal, thoracic). Confirm that the patient is ambulating, that mechanical and pharmacologic VTE prophylaxis has been discontinued or is no longer required, and that wound hemostasis is intact. Draw CBC 3 to 6 weeks after the first post-op injection.

Emergent Surgery: When There Is No Hold Window

Emergent cases, appendicitis, trauma, bowel obstruction, cannot accommodate a planned hold. The anesthesiology team needs to know the patient is on testosterone enanthate so they can: (a) order a stat hematocrit before induction, (b) anticipate elevated blood viscosity if hematocrit is above 52%, (c) ensure strong intraoperative and post-operative VTE prophylaxis, and (d) flag the case for post-op hematology review if erythrocytosis is significant.

Intraoperative Considerations

Blood viscosity rises non-linearly above hematocrit of 50%, increasing resistance in microcirculation and raising the work of the heart [10]. For patients with concurrent cardiac disease, this effect may be clinically significant. Intraoperative hemodilution with isotonic crystalloid can partially mitigate elevated viscosity, though this decision belongs to the anesthesiologist of record.

Anticoagulation Overlap

Patients already on therapeutic anticoagulation for atrial fibrillation or prior VTE who also take testosterone enanthate present a layered pharmacologic picture. The anticoagulant addresses fibrin-clot formation but does not correct the viscosity or platelet effects of erythrocytosis. This combination warrants an explicit pre-op hematology note documenting the expected trajectory of hematocrit after the hold and any plan for phlebotomy.

Testosterone Enanthate vs. Other Formulations: Does the Hold Differ?

Shorter-Acting Esters and Gels

Testosterone cypionate (half-life approximately 8 days) and testosterone propionate (half-life approximately 2 days) differ from enanthate (half-life approximately 4.5 days) in washout kinetics, but the erythropoietic effect lags all of them by weeks [1,11]. A 4-week minimum hold is therefore reasonable across IM ester formulations. Testosterone gels, because they produce lower and more stable serum levels, may confer lower erythrocytosis risk, though the T-Trials still documented a 5.9% rate of hematocrit above 54% even with gel formulations [8].

Pellet Implants

Subcutaneous testosterone pellets (Testopel) have no practical "hold" mechanism once implanted, the pellet continues releasing androgen for 3 to 6 months. Surgeons encountering a pellet patient should treat them as if on active testosterone with no possible washout, focus on hematocrit management (phlebotomy if above 54%), and apply maximal VTE prophylaxis protocols.

Testosterone Undecanoate (Aveed)

Testosterone undecanoate IM (Aveed, 750 mg every 10 weeks) has a half-life of approximately 21 days [12]. Achieving pharmacokinetic washout before surgery would require stopping more than 10 weeks in advance, often impractical for quarterly dosing. In practice, surgical teams schedule around dosing cycles where possible and manage hematocrit directly.

Patient Counseling Points During the Hold

Patients stopping testosterone enanthate for 4 to 6 weeks will notice some combination of fatigue, reduced libido, mood changes, and possible mild hot flashes if hypogonadism was symptomatic before starting TRT. These symptoms are expected and reversible [3]. Setting realistic expectations reduces unnecessary calls to the prescribing provider during the hold window.

Patients should be told explicitly not to self-administer any testosterone during the hold period, including over-the-counter topical products that may contain androgenic compounds, because even low-dose exposure maintains erythropoietic drive. Anabolic steroid use, legal or otherwise, should be disclosed at the pre-op visit.

Monitoring Parameters at Each Phase

Pre-hold baseline labs should include: CBC with differential, serum testosterone (total and free), LH, FSH, PSA, lipid panel, and a basic metabolic panel. The LH and FSH values document the degree of HPG axis suppression and help predict how long recovery will take if the patient eventually wants to discontinue TRT entirely.

One week before surgery: repeat CBC is the minimum. If hematocrit was elevated at baseline, add a coagulation profile (PT, aPTT, fibrinogen, D-dimer) to screen for subclinical hypercoagulability.

Post-operatively at 3 to 6 weeks after first restart injection: CBC, serum testosterone trough (drawn just before the next scheduled injection), and PSA if age-appropriate. Document this in the surgical record as the formal "restart clearance" note.

Special Populations

Men 65 and Older

The T-Trials population, men 65 and older with testosterone below 275 ng/dL, experienced the highest rates of hematocrit elevation [8]. This age group also carries baseline higher surgical risk for VTE due to reduced ambulation, venous insufficiency, and polypharmacy. The 6-week hold (rather than 4 weeks) is preferred for this population, and pre-op phlebotomy should be considered proactively if baseline hematocrit exceeds 50%.

Transgender Men

Transgender men on testosterone enanthate for gender-affirming hormone therapy undergo the same pharmacologic effects as cisgender men on TRT. The perioperative hold recommendation is identical. Gender-affirming surgical teams have developed specialized protocols; the American College of Obstetricians and Gynecologists notes that testosterone use is associated with increased hematocrit and recommends monitoring before surgical procedures in this population [13].

Patients With Prior VTE

A personal history of deep vein thrombosis or pulmonary embolism is a relative contraindication to testosterone therapy in some guidelines. For this subgroup scheduled for surgery, the prescribing provider, hematologist, and surgeon should jointly determine whether testosterone should be permanently discontinued rather than temporarily held.

Regulatory and Label Context

The FDA approved testosterone enanthate injection under NDA and requires all testosterone products to carry a black-box warning regarding secondary exposure risk and a general warning about cardiovascular risk [9]. The 2015 FDA Drug Safety Communication stated that the agency had concluded "that the benefits and risks of testosterone products should be clearly communicated to patients and providers" given post-marketing reports of strokes, heart attacks, and VTE [9].

The Endocrine Society 2018 guideline states directly: "We suggest against starting testosterone therapy in patients who are planning surgery in the near future due to the increased risk of venous thromboembolism" [3]. The guideline does not specify an exact number of weeks but places the hold recommendation within the broader context of hematocrit management and individualized risk stratification.